Brokers Set Expectations for DNLI FY2025 Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Denali Therapeutics in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will post earnings per share of ($2.86) for the year. Cantor Fitzgerald has a “Neutral” rating on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.73) per share.

DNLI has been the topic of a number of other reports. William Blair reissued an “outperform” rating on shares of Denali Therapeutics in a research note on Wednesday, January 15th. Jefferies Financial Group lifted their price target on Denali Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Friday, November 1st. Raymond James restated a “market perform” rating on shares of Denali Therapeutics in a research report on Thursday, October 10th. Robert W. Baird assumed coverage on Denali Therapeutics in a research report on Tuesday, January 7th. They issued an “outperform” rating and a $31.00 target price on the stock. Finally, Stifel Nicolaus raised Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 target price for the company in a research note on Monday, December 16th. Two equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $38.91.

Denali Therapeutics Stock Up 5.1 %

DNLI stock opened at $23.04 on Wednesday. The company’s 50-day moving average price is $22.80 and its two-hundred day moving average price is $24.81. Denali Therapeutics has a 12 month low of $14.56 and a 12 month high of $33.33. The firm has a market cap of $3.32 billion, a P/E ratio of -8.35 and a beta of 1.39.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same quarter last year, the business earned ($0.72) earnings per share.

Insiders Place Their Bets

In related news, insider Alexander O. Schuth sold 15,558 shares of the firm’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $29.91, for a total transaction of $465,339.78. Following the completion of the transaction, the insider now directly owns 178,066 shares of the company’s stock, valued at $5,325,954.06. This trade represents a 8.04 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Steve E. Krognes sold 3,339 shares of the company’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $20.81, for a total value of $69,484.59. Following the completion of the sale, the director now owns 25,757 shares in the company, valued at $536,003.17. This trade represents a 11.48 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 64,518 shares of company stock valued at $1,469,382 in the last ninety days. 7.90% of the stock is currently owned by insiders.

Institutional Trading of Denali Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. CWM LLC raised its position in shares of Denali Therapeutics by 43.6% in the 3rd quarter. CWM LLC now owns 2,153 shares of the company’s stock worth $63,000 after acquiring an additional 654 shares in the last quarter. Quest Partners LLC acquired a new stake in Denali Therapeutics during the third quarter worth approximately $73,000. Assetmark Inc. increased its holdings in Denali Therapeutics by 18.0% in the third quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock worth $111,000 after purchasing an additional 580 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Denali Therapeutics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock valued at $152,000 after buying an additional 920 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Denali Therapeutics during the 2nd quarter worth approximately $194,000. 92.92% of the stock is currently owned by institutional investors.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.